TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentato sab 7 nov · 15:45 GMT-6LBS.03 Late-breaking Science: Hot Topics in CVD PreventionTutti gli studi Late-Breaking Science →

Ez-PAVE

2026

Ez-PAVE: Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease, prespecified second randomisation

In patients with atherosclerotic cardiovascular disease, initial statin-ezetimibe combination therapy did not reduce the 3-year composite of cardiovascular death, myocardial infarction, stroke, revascularisation or hospitalisation for unstable angina compared with statin monotherapy.

Risultato

Efficacia: Cardiovascular outcomes within 3 yearshazard ratio 1,07 (IC 95% 0,83-1,37) · P = 0,596

Sotto 1 a favore di initial statin-ezetimibe combination therapy, sopra 1 a favore di statin monotherapy.

Tassi di eventi
Differenza assoluta
0,6 punti

La differenza assoluta è derivata dai tassi di eventi.

Riportato inoltre: Median LDL-C during follow-up was 53 mg/dL (interquartile range 45-62) vs 62 mg/dL (interquartile range 53-74) with intensive targeting, and 63 mg/dL (interquartile range 55-73) vs 70 mg/dL (interquartile range 62-81) with conventional targeting. The safety end points were similar between the groups.

Pubblicazione originale
Sottotema
Ezetimibe combination
Disegno
Open-label 2-by-2 factorial randomised trial in Korea (Yonsei University). First randomisation: LDL-C target below 55 versus below 70 mg/dL. The prespecified second randomisation, presented here: statin-ezetimibe combination versus statin monotherapy
Arruolati
3048 pazienti
Fonte
Lee SH, Byun YS, et al. Circulation. 2026; published online 7 November.doi 10.1161/CIRCULATIONAHA.126.083811

Discussione e critica

Starting with statin-ezetimibe combination therapy lowered LDL-C during follow-up under both targeting strategies but did not reduce the primary composite endpoint compared with statin monotherapy. The composite includes any revascularisation and hospitalisation for unstable angina, so softer components may weigh on the total, and the abstract does not break the endpoint down into its components. Follow-up is three years, which may be too short to show a difference in hard outcomes from a modest gap in LDL-C. The abstract reports safety only as similar between groups and gives no figures.

Discusso nei podcast